Nuclera

Nuclera exists to remove uncertainty from protein science. As the pioneer of multiplex protein screening, they help researchers start with clarity, so ideas move faster to result. Founded in 2013 at the University of Cambridge, Nuclera aims to deliver a multiplex protein screening system that turns months of iteration into days. They offer services such as rapid antibody screening, which converts digital sequences into decision-grade binding data from just 14 business days.

Nuclera was founded in 2013 at the University of Cambridge by Michael Chen, Jiahao Huang, and Gordon Herling-McInroy. In 2014, Nuclera raised $600K in Seed funding led by angel investors. In 2018, Nuclera raised $12M in Series A funding led by RT Partners. In 2020, the British Business Bank and E Ink invested $12M into Nuclera through the UK Future Fund. In 2021, Nuclera acquired digital microfluidic intellectual property, equipment, and team from its strategic partner, E Ink, and opened its first subsidiary in Boston, Massachusetts. In 2022, Nuclera raised a total of $58M in two rounds of Series B funding.

1. About us | Nuclera
2. Antibody Screening Service
3. Nuclera (United Kingdom)